Da Rentang announced that Xinxin Pharmaceutical Factory, a branch of the company, recently received the “Drug Registration Certificate” for saxagliptin metformin sustained-release tablets approved and issued by the State Drug Administration. The drug is suitable for adults with type 2 diabetes. The total domestic sales volume in 2025 is about 480 million yuan, an increase of about 33% over the previous year. Once approved, it is considered to have passed the consistency evaluation and will not have a significant impact on the company's recent performance. Drugs are approved for production and sale or are affected by uncertainties, and the future scale of production and sales is uncertain.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.